A detailed history of Pathstone Family Office, LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Pathstone Family Office, LLC holds 3,275 shares of BMRN stock, worth $207,700. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,275
Holding current value
$207,700
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 08, 2023

BUY
$85.07 - $94.48 $278,604 - $309,422
3,275 New
3,275 $289,000
Q1 2021

May 14, 2021

SELL
$74.73 - $90.69 $5,305 - $6,438
-71 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$72.61 - $90.2 $10,891 - $13,530
-150 Reduced 67.87%
71 $6,000
Q3 2020

Nov 12, 2020

SELL
$71.87 - $131.03 $204,829 - $373,435
-2,850 Reduced 92.8%
221 $16,000
Q1 2020

Jun 11, 2020

BUY
$71.37 - $96.85 $214,110 - $290,550
3,000 Added 4225.35%
3,071 $260,000
Q1 2020

May 07, 2020

BUY
$71.37 - $96.85 $5,067 - $6,876
71 New
71 $6 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $11.8B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Pathstone Family Office, LLC Portfolio

Follow Pathstone Family Office, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathstone Family Office, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pathstone Family Office, LLC with notifications on news.